Aurinia Pharmaceuticals (AUPH) Data Continues to Filter Out Bearish Concerns - Leerink

October 6, 2016 9:30 AM EDT
Get Alerts AUPH Hot Sheet
Price: $3.44 -6.27%

Rating Summary:
    2 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 23 | New: 30
Trade AUPH Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $7 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) after data presented today at the European Lupus Meeting shows 70% of patients. (n=7/10) achieved complete remission (CR) at 24 weeks vs. 57% (n=4/7) reported back in July.

"We believe this data further supports the efficacy behind voclosporin in lupus nephritis (LN) and should help remove the cautious sentiment surrounding the stock since the Ph.2b AURA-LV data announcement," Schwartz commented.

For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals click here. For more ratings news on Aurinia Pharmaceuticals click here.

Shares of Aurinia Pharmaceuticals closed at $4.05 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Add Your Comment